Tumor microenvironment and therapeutic response

Hallmarks of Cancer: The Next Generation

Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590 · see citing works

Microenvironmental regulation of tumor progression and metastasis

Quail, D. F., & Joyce, J. A. (2013) · Nature Medicine · doi:10.1038/nm.3394 · Cited by 7,994 · see citing works

Macrophage Diversity Enhances Tumor Progression and Metastasis

Qian, B., & Pollard, J. W. (2010) · Cell · doi:10.1016/j.cell.2010.03.014 · Cited by 5,208 · see citing works

Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment

Hanahan, D., & Coussens, L. M. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.022 · Cited by 4,632 · see citing works

Fibroblasts in cancer

Kalluri, R., & Zeisberg, M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1877 · Cited by 4,538 · see citing works

Stromal Fibroblasts Present in Invasive Human Breast Carcinomas Promote Tumor Growth and Angiogenesis through Elevated SDF-1/CXCL12 Secretion

Orimo, A., Gupta, P. B., Sgroi, D. C., Arenzana-Seisdedos, F., Delaunay, T., Naeem, R., Carey, V. J., Richardson, A. L., & Weinberg, R. A. (2005) · Cell · doi:10.1016/j.cell.2005.02.034 · Cited by 3,759 · see citing works

Coordinated regulation of myeloid cells by tumours

Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012) · Nature Reviews Immunology · doi:10.1038/nri3175 · Cited by 3,544 · see citing works

Immunogenic Cell Death in Cancer Therapy

Kroemer, G., Galluzzi, L., Kepp, O., & Zitvogel, L. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-100008 · Cited by 3,303 · see citing works

CSF-1R inhibition alters macrophage polarization and blocks glioma progression

Pyonteck, S. M., Akkari, L., Schuhmacher, A. J., Bowman, R. L., Sevenich, L., Quail, D. F., Olson, O. C., Quick, M. L., Huse, J. T., Teijeiro, V., et al. (2013) · Nature Medicine · doi:10.1038/nm.3337 · Cited by 2,463 · see citing works

Macrophage plasticity and polarization in tissue repair and remodelling

Mantovani, A., Biswas, S. K., Galdiero, M. R., Sica, A., & Locati, M. (2013) · The Journal of Pathology · doi:10.1002/path.4133 · Cited by 2,384 · see citing works

Putting tumours in context

Bissell, M. J., & Radisky, D. (2001) · Nature Reviews Cancer · doi:10.1038/35094059 · Cited by 2,180 · see citing works

Drug Resistance and the Solid Tumor Microenvironment

Tredan, O., Galmarini, C. M., Patel, K., & Tannock, I. F. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm135 · Cited by 2,116 · see citing works

Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion

Straussman, R., Morikawa, T., Shee, K., Barzily-Rokni, M., Qian, Z. R., Du, J., Davis, A., Mongare, M. M., Gould, J., Frederick, D. T., et al. (2012) · Nature · doi:10.1038/nature11183 · Cited by 1,771 · see citing works

Leukocyte Complexity Predicts Breast Cancer Survival and Functionally Regulates Response to Chemotherapy

DeNardo, D. G., Brennan, D. J., Rexhepaj, E., Ruffell, B., Shiao, S. L., Madden, S. F., Gallagher, W. M., Wadhwani, N., Keil, S. D., Junaid, S. A., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8274.cd-10-0028 · Cited by 1,715 · see citing works

CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans

Beatty, G. L., Chiorean, E. G., Fishman, M. P., Saboury, B., Teitelbaum, U. R., Sun, W., Huhn, R. D., Song, W., Li, D., Sharp, L. L., et al. (2011) · Science · doi:10.1126/science.1198443 · Cited by 1,678 · see citing works

Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy.

Ries, C. H., Cannarile, M. A., Hoves, S., Benz, J., Wartha, K., Runza, V., Rey-Giraud, F., Pradel, L. P., Feuerhake, F., Klaman, I., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.05.016 · Cited by 1,384 · see citing works

Macrophage polarization in tumour progression

Sica, A., Larghi, P., Mancino, A., Rubino, L., Porta, C., Totaro, M. G., Rimoldi, M., Biswas, S. K., Allavena, P., & Mantovani, A. (2008) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2008.03.004 · Cited by 1,241 · see citing works

Extracellular matrix and cell signalling: the dynamic cooperation of integrin, proteoglycan and growth factor receptor

Kim, S., Turnbull, J. E., & Guimond, S. E. (2011) · Journal of Endocrinology · doi:10.1530/joe-10-0377 · Cited by 1,166 · see citing works

Role of extracellular matrix assembly in interstitial transport in solid tumors.

Netti, P. A., Berk, D. A., Swartz, M. A., Grodzinsky, A. J., & Jain, R. K. (2000) · PubMed · Cited by 1,165 · see citing works

History of myeloid-derived suppressor cells

Talmadge, J. E., & Gabrilovich, D. I. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3581 · Cited by 1,148 · see citing works

Immunological hallmarks of stromal cells in the tumour microenvironment

Turley, S. J., Cremasco, V., & Astarita, J. L. (2015) · Nature Reviews Immunology · doi:10.1038/nri3902 · Cited by 1,140 · see citing works

A CXCL1 Paracrine Network Links Cancer Chemoresistance and Metastasis

Acharyya, S., Oskarsson, T., Vanharanta, S., Malladi, S., Kim, J., Morris, P. G., Manova-Todorova, K., Leversha, M., Hogg, N., Seshan, V. E., et al. (2012) · Cell · doi:10.1016/j.cell.2012.04.042 · Cited by 1,085 · see citing works

Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial

Stupp, R., Hegi, M. E., Gorlia, T., Erridge, S. C., Perry, J., Hong, Y.-K., Aldape, K. D., Lhermitte, B., Pietsch, T., Grujicic, D., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70379-1 · Cited by 1,052 · see citing works

Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells

Ruffell, B., Chang-Strachan, D., Chan, V., Rosenbusch, A., Ho, C. M. T., Pryer, N., Daniel, D., Hwang, E. S., Rugo, H. S., & Coussens, L. M. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.09.006 · Cited by 1,008 · see citing works

Tumor Induction of VEGF Promoter Activity in Stromal Cells

Fukumura, D., Xavier, R., Sugiura, T., Chen, Y., Park, E.-C., Lu, N., Selig, M., Nielsen, G., Taksir, T., Jain, R. K., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81731-6 · Cited by 996 · see citing works

Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer

Bayne, L. J., Beatty, G. L., Jhala, N., Clark, C. E., Rhim, A. D., Stanger, B. Z., & Vonderheide, R. H. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.04.025 · Cited by 947 · see citing works

Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer

Bracci, L., Schiavoni, G., Sistigu, A., & Belardelli, F. (2013) · Cell Death and Differentiation · doi:10.1038/cdd.2013.67 · Cited by 931 · see citing works

Environment-mediated drug resistance: A major contributor to minimal residual disease

Meads, M. B., Gatenby, R. A., & Dalton, W. S. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2714 · Cited by 892 · see citing works

Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells

Shojaei, F., Wu, X., Malik, A. K., Zhong, C., Baldwin, M. E., Schanz, S., Fuh, G., Gerber, H.-P., & Ferrara, N. (2007) · Nature Biotechnology · doi:10.1038/nbt1323 · Cited by 849 · see citing works

“Re-educating” tumor-associated macrophages by targeting NF-κB

Hagemann, T., Lawrence, T., McNeish, I., Charles, K. A., Kulbe, H., Thompson, R. G., Robinson, S. C., & Balkwill, F. R. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20080108 · Cited by 792 · see citing works

Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth

Bruchard, M., Mignot, G., Dérangère, V., Chalmin, F., Chevriaux, A., Végran, F., Boireau, W., Simon, B., Ryffel, B., Connat, J., et al. (2012) · Nature Medicine · doi:10.1038/nm.2999 · Cited by 775 · see citing works

Microenvironmental regulation of therapeutic response in cancer

Klemm, F., & Joyce, J. A. (2014) · Trends in Cell Biology · doi:10.1016/j.tcb.2014.11.006 · Cited by 769 · see citing works

Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function

Serafini, P., Meckel, K. F., Kelso, M., Noonan, K. A., Califano, J. A., Koch, W. M., Dolcetti, L., Bronte, V., & Borrello, I. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20061104 · Cited by 767 · see citing works

Disruption of CXCR2-Mediated MDSC Tumor Trafficking Enhances Anti-PD1 Efficacy

Highfill, S. L., Cui, Y., Giles, A. J., Smith, J. P., Zhang, H., Morse, E., Kaplan, R. N., & Mackall, C. L. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007974 · Cited by 767 · see citing works

Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell–derived factor-1

Burger, J. A., Tsukada, N., Burger, M., Zvaifler, N. J., Dell’Aquila, M. L., & Kipps, T. J. (2000) · Blood · doi:10.1182/blood.v96.8.2655 · Cited by 758 · see citing works

Macrophages and cancer: from mechanisms to therapeutic implications

Ostuni, R., Kratochvill, F., Murray, P. J., & Natoli, G. (2015) · Trends in Immunology · doi:10.1016/j.it.2015.02.004 · Cited by 685 · see citing works

Bv8 regulates myeloid-cell-dependent tumour angiogenesis

Shojaei, F., Wu, X., Zhong, C., Yu, L., Liang, X., Yao, J. J., Blanchard, D., Bais, C., Peale, F. V., Jr., van Bruggen, N., et al. (2007) · Nature · doi:10.1038/nature06348 · Cited by 640 · see citing works

Targeting tumor‐associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake

Loeffler, M. (2006) · Journal of Clinical Investigation · doi:10.1172/jci26532 · Cited by 633 · see citing works

The interaction of anticancer therapies with tumor-associated macrophages

Mantovani, A., & Allavena, P. (2015) · The Journal of Experimental Medicine · doi:10.1084/jem.20150295 · Cited by 617 · see citing works

Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia

Matsunaga, T., Takemoto, N., Sato, T., Takimoto, R., Tanaka, I., Fujimi, A., Akiyama, T., Kuroda, H., Kawano, Y., Kobune, M., et al. (2003) · Nature Medicine · doi:10.1038/nm909 · Cited by 564 · see citing works

Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma

Dankbar, B., Padró, T., Leo, R., Feldmann, B., Kropff, M. H., Mesters, R. M., Serve, H. L., Berdel, W. E., & Kienast, J. (2000) · Blood · doi:10.1182/blood.v95.8.2630 · Cited by 562 · see citing works

Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer

Shree, T., Olson, O. C., Elie, B. T., Kester, J. C., Garfall, A. L., Simpson, K., Bell-McGuinn, K. M., Zabor, E. C., Brogi, E., & Joyce, J. A. (2011) · Genes & Development · doi:10.1101/gad.180331.111 · Cited by 541 · see citing works

Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML

Zeng, Z., Shi, Y. X., Samudio, I. J., Wang, R., Ling, X., Frolova, O., Levis, M. J., Rubin, J. B., Negrin, R. S., Estey, E. H., et al. (2008) · Blood · doi:10.1182/blood-2008-05-158311 · Cited by 518 · see citing works

Activation of fibroblasts in cancer stroma

Räsänen, K., & Vaheri, A. (2010) · Experimental Cell Research · doi:10.1016/j.yexcr.2010.04.032 · Cited by 499 · see citing works

Endothelial expression of PD‐L1 and PD‐L2 down‐regulates CD8+ T cell activation and cytolysis

Rodig, N., Ryan, T., Allen, J. A., Pang, H. B., Grabie, N., Chernova, T., Greenfield, E. A., Liang, S. C., Sharpe, A. H., Lichtman, A. H., et al. (2003) · European Journal of Immunology · doi:10.1002/eji.200324270 · Cited by 494 · see citing works

Tumor-associated macrophages regulate tumorigenicity and anticancer drug responses of cancer stem/initiating cells

Jinushi, M., Chiba, S., Yoshiyama, H., Masutomi, K., Kinoshita, I., Dosaka-Akita, H., Yagita, H., Takaoka, A., & Tahara, H. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1106645108 · Cited by 479 · see citing works

Imaging Tumor-Stroma Interactions during Chemotherapy Reveals Contributions of the Microenvironment to Resistance

Nakasone, E. S., Askautrud, H. A., Kees, T., Park, J.-H., Plaks, V., Ewald, A. J., Fein, M. R., Rasch, M. G., Tan, Y.-X., Qiu, J., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.017 · Cited by 477 · see citing works

G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models

Shojaei, F., Wu, X., Qu, X., Kowanetz, M., Yu, L., Tan, M., Meng, Y. G., & Ferrara, N. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0902280106 · Cited by 473 · see citing works

PGE2-Induced CXCL12 Production and CXCR4 Expression Controls the Accumulation of Human MDSCs in Ovarian Cancer Environment

Obermajer, N., Muthuswamy, R., Odunsi, K. O., Edwards, R. P., & Kaliński, P. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-2449 · Cited by 465 · see citing works

A Phase I Study of an Agonist CD40 Monoclonal Antibody (CP-870,893) in Combination with Gemcitabine in Patients with Advanced Pancreatic Ductal Adenocarcinoma

Beatty, G. L., Torigian, D. A., Chiorean, E. G., Saboury, B., Brothers, A., Alavi, A. A., Troxel, A. B., Sun, W., Teitelbaum, U. R., Vonderheide, R. H., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1320 · Cited by 458 · see citing works

Autophagy and cellular immune responses

Ma, Y., Galluzzi, L., Zitvogel, L., & Kroemer, G. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.017 · Cited by 447 · see citing works

An interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy

Chung, A. S., Wu, X., Zhuang, G., Ngu, H., Kasman, I., Zhang, J., Vernes, J.-M., Jiang, Z., Meng, Y. G., Peale, F. V., et al. (2013) · Nature Medicine · doi:10.1038/nm.3291 · Cited by 445 · see citing works

Mechanism of All- Trans Retinoic Acid Effect on Tumor-Associated Myeloid-Derived Suppressor Cells

Nefedova, Y., Fishman, M., Sherman, S., Wang, X., Beg, A. A., & Gabrilovich, D. I. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-2593 · Cited by 425 · see citing works

Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer

Pienta, K. J., Machiels, J.-P., Schrijvers, D. L. A. L., Alekseev, B. Y., Shkolnik, M. I., Crabb, S. J., Li, S., Seetharam, S., Puchalski, T. A., Takimoto, C. H. M., et al. (2012) · Investigational New Drugs · doi:10.1007/s10637-012-9869-8 · Cited by 413 · see citing works

Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration

Podar, K., Tai, Y., Davies, F. E., Lentzsch, S., Sattler, M., Hideshima, T., Lin, B. K., Gupta, D. K., Shima, Y., Chauhan, D., et al. (2001) · Blood · doi:10.1182/blood.v98.2.428 · Cited by 412 · see citing works

Microvessel density and VEGF expression are prognostic factors in colorectal cancer. Meta-analysis of the literature

Guetz, G. D., Uzzan, B., Nicolas, P., Cucherat, M., Morère, J., Benamouzig, R., Breau, J. L., & Perret, G.-Y. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603176 · Cited by 406 · see citing works

IL-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade

Ogata, A., Chauhan, D., Teoh, G. K. H., Treon, S. P., Urashima, M., Schlossman, R. L., & Anderson, K. C. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.159.5.2212 · Cited by 399 · see citing works

A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia

Uy, G. L., Rettig, M. P., Motabi, I., McFarland, K., Trinkaus, K. M., Hladnik, L. M., Kulkarni, S., Abboud, C. N., Cashen, A. F., Stockerl-Goldstein, K. E., et al. (2012) · Blood · doi:10.1182/blood-2011-10-383406 · Cited by 399 · see citing works

COX-2 Blockade Suppresses Gliomagenesis by Inhibiting Myeloid-Derived Suppressor Cells

Fujita, M., Kohanbash, G., Fellows-Mayle, W. K., Hamilton, R. L., Komohara, Y., Decker, S. A., Ohlfest, J. R., & Okada, H. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3055 · Cited by 386 · see citing works

CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study

Cassier, P. A., Italiano, A., Gomez‐Roca, C., Tourneau, C. L., Toulmonde, M., Cannarile, M. A., Ries, C. H., Brillouet, A., Müller, C., Jegg, A.-M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00132-1 · Cited by 368 · see citing works

Targeting distinct tumor-infiltrating myeloid cells by inhibiting CSF-1 receptor: combating tumor evasion of antiangiogenic therapy

Priceman, S. J., Sung, J. L., Shaposhnik, Z., Burton, J. B., Torres‐Collado, A. X., Moughon, D. L., Johnson, M., Lusis, A. J., Cohen, D. A., Iruela‐Arispe, M. L., et al. (2009) · Blood · doi:10.1182/blood-2009-08-237412 · Cited by 357 · see citing works

Chemotherapy Alters Monocyte Differentiation to Favor Generation of Cancer-Supporting M2 Macrophages in the Tumor Microenvironment

Dijkgraaf, E. M., Heusinkveld, M., Tummers, B., Vogelpoel, L. T. C., Goedemans, R., Jha, V., Nortier, J. W. R., Welters, M. J. P., Kroep, J. R., & van der Burg, S. H. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3542 · Cited by 346 · see citing works

Interleukin 4 protects chronic lymphocytic leukemic B cells from death by apoptosis and upregulates Bcl-2 expression.

Dancescu, M., Rubio, M., Biron, G., Bron, D., Delespesse, G., & Sarfati, M. (1992) · The Journal of Experimental Medicine · doi:10.1084/jem.176.5.1319 · Cited by 344 · see citing works

Remodeling of the extracellular matrix through overexpression of collagen VI contributes to cisplatin resistance in ovarian cancer cells

Sherman‐Baust, C. A., Weeraratna, A. T., Rangel, L. B. A., Pizer, E. S., Cho, K. R., Schwartz, D. R., Shock, T. L., & Morin, P. J. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00058-8 · Cited by 340 · see citing works

HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironment

Weigelt, B., Lo, A. T., Park, C. C., Gray, J. W., & Bissell, M. J. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0502-2 · Cited by 336 · see citing works

Interferon‐γ reverses the immunosuppressive and protumoral properties and prevents the generation of human tumor‐associated macrophages

Duluc, D., Corvaisier, M., Blanchard, S., Catala, L., Descamps, P., Gamelin, E. C., Ponsoda, S., Delneste, Y., Hebbar, M., & Jeannin, P. (2009) · International Journal of Cancer · doi:10.1002/ijc.24401 · Cited by 328 · see citing works

Integrin signaling inhibits paclitaxel-induced apoptosis in breast cancer cells

Aoudjit, F., & Vuori, K. (2001) · Oncogene · doi:10.1038/sj.onc.1204554 · Cited by 325 · see citing works

Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancer

Iclozan, C., Antonia, S. J., Chiappori, A., Chen, D., & Gabrilovich, D. I. (2013) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-013-1396-8 · Cited by 318 · see citing works

Nurselike cells express BAFF and APRIL, which can promote survival of chronic lymphocytic leukemia cells via a paracrine pathway distinct from that of SDF-1α

Nishio, M., Endo, T., Tsukada, N., Ohata, J., Kitada, S., Reed, J. C., Zvaifler, N. J., & Kipps, T. J. (2005) · Blood · doi:10.1182/blood-2004-03-0889 · Cited by 316 · see citing works

Tumor angiogenesis is accompanied by a decreased inflammatory response of tumor-associated endothelium

Griffioen, A. W., Damen, C. A., Blijham, G. H., & Groenewegen, G. (1996) · Blood · doi:10.1182/blood.v88.2.667.bloodjournal882667 · Cited by 306 · see citing works

Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells

Burger, M., Hartmann, T. N., Krome, M., Rawluk, J. K., Tamamura, H., Fujii, N., Kipps, T. J., & Burger, J. A. (2005) · Blood · doi:10.1182/blood-2004-12-4918 · Cited by 295 · see citing works

Anti-inflammatory Triterpenoid Blocks Immune Suppressive Function of MDSCs and Improves Immune Response in Cancer

Nagaraj, S., Youn, J., Weber, H., Iclozan, C., Lu, L. D., Cotter, M. J., Meyer, C. J., Becerra, C. R., Fishman, M., Antonia, S. J., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-3272 · Cited by 286 · see citing works

Macrophages mediate gemcitabine resistance of pancreatic adenocarcinoma by upregulating cytidine deaminase

Weizman, N., Krelin, Y., Shabtay-Orbach, A., Amit, M., Binenbaum, Y., Wong, R. J., & Gil, Z. (2014) · Oncogene · doi:10.1038/onc.2013.357 · Cited by 281 · see citing works

MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy

Finke, J. H., Ko, J. S., Rini, B. I., Rayman, P. A., Ireland, J. L., & Cohen, P. A. (2011) · International Immunopharmacology · doi:10.1016/j.intimp.2011.01.030 · Cited by 281 · see citing works

A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors

Sandhu, S. K., Papadopoulos, K. P., Fong, P. C. C., Patnaik, A., Messiou, C., Olmos, D., Wang, G., Tromp, B. J., Puchalski, T. A., Balkwill, F. R., et al. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2099-8 · Cited by 273 · see citing works

The Penetration of Anticancer Drugs through Tumor Tissue as a Function of Cellular Adhesion and Packing Density of Tumor Cells

Grantab, R., Sivananthan, S., & Tannock, I. F. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3077 · Cited by 254 · see citing works

Generation of a new therapeutic peptide that depletes myeloid-derived suppressor cells in tumor-bearing mice

Qin, H., Lerman, B., Sakamaki, I., Wei, G., Cha, S. C., Rao, S. S., Qian, J., Hailemichael, Y., Nurieva, R., Dwyer, K. C., et al. (2014) · Nature Medicine · doi:10.1038/nm.3560 · Cited by 234 · see citing works

Colony-Stimulating Factor-1 Antibody Reverses Chemoresistance in Human MCF-7 Breast Cancer Xenografts

Paulus, P., Stanley, E. R., Schäfer, R., Abraham, D., & Aharinejad, S. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3523 · Cited by 231 · see citing works

Increase in tumor-associated macrophages after antiangiogenic therapy is associated with poor survival among patients with recurrent glioblastoma

Lu‐Emerson, C., Snuderl, M., Kirkpatrick, N. D., Goveia, J., Davidson, C. J., Huang, Y., Riedemann, L., Taylor, J. M., Ivy, P. S., Duda, D. G., et al. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not082 · Cited by 226 · see citing works

Regulation of Multidrug Resistance in Cancer Cells by Hyaluronan

Misra, S., Ghatak, S., Zoltan-Jones, A., & Toole, B. P. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.c300173200 · Cited by 222 · see citing works

β1 Integrin Inhibition Dramatically Enhances Radiotherapy Efficacy in Human Breast Cancer Xenografts

Park, C. C., Zhang, H. J., Yao, E. S., Park, C. J., & Bissell, M. J. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6390 · Cited by 220 · see citing works

Tumor Endothelial Cells Express Epidermal Growth Factor Receptor (EGFR) but not ErbB3 and Are Responsive to EGF and to EGFR Kinase Inhibitors

Amin, D. N., Hida, K., Bielenberg, D. R., & Klagsbrun, M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3387 · Cited by 220 · see citing works

Carlumab, an anti-C-C chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label, multicenter phase 1b study

Braña, I., Calles, A., LoRusso, P. M., Yee, L., Puchalski, T. A., Seetharam, S., Zhong, B., de Boer, C. J., Tabernero, J. M., & Calvo, E. (2014) · Targeted Oncology · doi:10.1007/s11523-014-0320-2 · Cited by 218 · see citing works

A Combination of Chemoimmunotherapies Can Efficiently Break Self-Tolerance and Induce Antitumor Immunity in a Tolerogenic Murine Tumor Model

Ko, H., Kim, Y., Kim, Y.-S., Chang, W., Ko, S., Chang, S., Sakaguchi, S., & Kang, C. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4639 · Cited by 203 · see citing works

CXCR4 downregulation of let-7a drives chemoresistance in acute myeloid leukemia

Chen, Y., Jacamo, R. O., Konopleva, M. Y., Garzon, R., Croce, C. M., & Andreeff, M. (2013) · Journal of Clinical Investigation · doi:10.1172/jci66553 · Cited by 202 · see citing works

Prognostic Value of Vascular Endothelial Growth Factor Expression in Patients with Lung Cancer: A Systematic Review with Meta-Analysis

Zhan, P., Wang, J., Lv, X.-J., Wang, Q., Qiu, L., Lin, X.-Q., Yu, L.-K., & Song, Y. (2009) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181a97e31 · Cited by 192 · see citing works

A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin αvβ3, ± dacarbazine in patients with stage IV metastatic melanoma

Hersey, P., Sosman, J. A., O'Day, S. J., Richards, J. M., Bedikian, A. Y., Gonzalez, R. C., Sharfman, W. H., Weber, R. W., Logan, T. F., Buzoianu, M., et al. (2010) · Cancer · doi:10.1002/cncr.24821 · Cited by 190 · see citing works

Cytogenetic Abnormalities of Tumor-Associated Endothelial Cells in Human Malignant Tumors

Akino, T., Hida, K., Hida, Y., Tsuchiya, K., Freedman, D. A., Muraki, C., Ohga, N., Matsuda, K., Akiyama, K., Harabayashi, T., et al. (2009) · American Journal Of Pathology · doi:10.2353/ajpath.2009.090202 · Cited by 183 · see citing works

Sensitizing Protective Tumor Microenvironments to Antibody-Mediated Therapy

Pallasch, C. P., Leskov, I. B., Braun, C. J., Vorholt, D., Drake, A. C. B., Soto‐Feliciano, Y. M., Bent, E. H., Schwamb, J., Iliopoulou, B. P., Kutsch, N., et al. (2014) · Cell · doi:10.1016/j.cell.2013.12.041 · Cited by 177 · see citing works

Basic fibroblast growth factor (bFGF) upregulates the expression of bcl-2 in B cell chronic lymphocytic leukemia cell lines resulting in delaying apoptosis

König, A. A., Menzel, T., Lynen, S., Wrazel, L., Rosén, A., Al-Katib, A. M., Raveche, E. S., & Jl, G. (1997) · Leukemia · doi:10.1038/sj.leu.2400556 · Cited by 173 · see citing works

Cancer Associated Fibroblasts express pro-inflammatory factors in human breast and ovarian tumors

Erez, N., Glanz, S., Raz, Y., Avivi, C., & Barshack, I. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.06.089 · Cited by 167 · see citing works

The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment

Anderson, K. C. (2003) · European Journal Of Haematology · doi:10.1034/j.1600-0609.2003.01067.x · Cited by 166 · see citing works

Tumor Endothelial Cells Acquire Drug Resistance by MDR1 Up-Regulation via VEGF Signaling in Tumor Microenvironment

Akiyama, K., Ohga, N., Hida, Y., Kawamoto, T., Sadamoto, Y., Ishikawa, S., Maishi, N., Akino, T., Kondoh, M., Matsuda, A., et al. (2012) · The American Journal of Pathology · doi:10.1016/j.ajpath.2011.11.029 · Cited by 154 · see citing works

Insulinlike growth factor–I signaling in multiple myeloma: downstream elements, functional correlates, and pathway cross-talk

Qiang, Y., Kopantzev, E. P., & Rudikoff, S. (2002) · Blood · doi:10.1182/blood.v99.11.4138 · Cited by 149 · see citing works

Phase 1B study to improve immune responses in head and neck cancer patients using escalating doses of 25-hydroxyvitamin D 3

Lathers, D. M. R., Clark, J. I., Achille, N. J., & Young, M. R. (2004) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-003-0459-7 · Cited by 149 · see citing works

Direct in vivo measurement of targeted binding in a human tumor xenograft

Berk, D. A., Fan, Y., Leunig, M., & Jain, R. K. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.5.1785 · Cited by 145 · see citing works

Fibroblast-mediated drug resistance in cancer

Paraiso, K. H. T., & Smalley, K. S. M. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.01.018 · Cited by 141 · see citing works

ECM overrides DNA damage-induced cell cycle arrest and apoptosis in small-cell lung cancer cells through β1 integrin-dependent activation of PI3-kinase

Hodkinson, P. S., Elliott, T., Wong, W. S., Rintoul, R. C., MacKinnon, A. C., Haslett, C., & Sethi, T. (2006) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401849 · Cited by 136 · see citing works

Paracrine interactions of basic fibroblast growth factor and interleukin-6 in multiple myeloma

Bisping, G., Leo, R., Wenning, D., Dankbar, B., Padró, T., Kropff, M. H., Scheffold, C., Kröger, M., Mesters, R. M., Berdel, W. E., et al. (2003) · Blood · doi:10.1182/blood-2002-09-2907 · Cited by 127 · see citing works

Anti‐ IL ‐6 receptor m A b eliminates myeloid‐derived suppressor cells and inhibits tumor growth by enhancing T ‐cell responses

Sumida, K., Wakita, D., Narita, Y., Masuko, K., Terada, S., Watanabe, K., Satoh, T., Kitamura, H., & Nishimura, T. (2012) · European Journal of Immunology · doi:10.1002/eji.201142335 · Cited by 126 · see citing works

Integrin alpha4 blockade sensitizes drug resistant pre-B acute lymphoblastic leukemia to chemotherapy

Hsieh, Y., Gang, E. J., Geng, H., Park, E., Huantes, S., Chudziak, D., Dauber, K., Schaefer, P., Scharman, C. D., Shimada, H., et al. (2013) · Blood · doi:10.1182/blood-2012-01-406272 · Cited by 124 · see citing works

On the origin of cancer-associated fibroblasts

Anderberg, C., & Pietras, K. (2009) · Cell Cycle · doi:10.4161/cc.8.10.8557 · Cited by 124 · see citing works

Enhancement of paclitaxel and carboplatin therapies by CCL2 blockade in ovarian cancers

Moisan, F., Francisco, E. B., Brozović, A., Durán, G. E., Wang, Y. C., Chaturvedi, S., Seetharam, S., Snyder, L. A., Doshi, P. D., & Sikic, B. I. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.03.016 · Cited by 118 · see citing works

Lapatinib and doxorubicin enhance the S tat1‐dependent antitumor immune response

Hannesdóttir, L., Tymoszuk, P., Parajuli, N., Wasmer, M.-H., Philipp, S., Daschil, N., Datta, S., Koller, J., Tripp, C. H., Stoitzner, P., et al. (2013) · European Journal of Immunology · doi:10.1002/eji.201242505 · Cited by 113 · see citing works

Interferon‐alpha up‐regulates bcl‐2 expression and protects B‐CLL cells from apoptosis in vitro and in vivo

Jewell, A. P., Worman, C. P., Lydyard, P. M., Yong, K., Giles, F. J., & Goldstone, A. H. (1994) · British Journal of Haematology · doi:10.1111/j.1365-2141.1994.tb05017.x · Cited by 107 · see citing works

Antitumor efficacy of the anti-interleukin-6 (IL-6) antibody siltuximab in mouse xenograft models of lung cancer

Song, L.-X., Smith, M., Doshi, P., Sasser, K., Fulp, W., Altiok, S., & Haura, E. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000193 · Cited by 94 · see citing works

Tenascin-C promotes melanoma progression by maintaining the ABCB5-positive side population

Fukunaga‐Kalabis, M., Martinez, G., Nguyen, T. K., Kim, D., Santiago-Walker, A., Roesch, A., & Herlyn, M. (2010) · Oncogene · doi:10.1038/onc.2010.350 · Cited by 94 · see citing works

Paracrine SDF-1α signaling mediates the effects of PSCs on GEM chemoresistance through an IL-6 autocrine loop in pancreatic cancer cells

Zhang, H., Wu, H., Guan, J., Wang, L., Ren, X., Shi, X., Liang, Z., & Liu, T. (2014) · Oncotarget · doi:10.18632/oncotarget.3099 · Cited by 93 · see citing works

Engagement of alpha4beta1 integrin by fibronectin induces in vitro resistance of B chronic lymphocytic leukemia cells to fludarabine.

de la Fuente, M. T., Casanova, B., Moyano, J. V., Garcı́a-Gila, M., Sanz, L., Garcia-Marco, J. A., Silva, A., & Garcı́a-Pardo, A. (2002) · PubMed · Cited by 90 · see citing works

Phase II study of Cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF prostate cancer clinical trials consortium

Alva, A. S., Slovin, S. F., Daignault, S. D., Carducci, M. A., DiPaola, R. S., Pienta, K. J., Agus, D. B., Cooney, K. A., Chen, A. P., Smith, D. C., et al. (2010) · Investigational New Drugs · doi:10.1007/s10637-010-9573-5 · Cited by 88 · see citing works

Anti-vascular endothelial growth factor therapy-induced glioma invasion is associated with accumulation of Tie2-expressing monocytes

Gabrusiewicz, K. R., Liu, D., Cortes‐Santiago, N., Hossain, M. B., Conrad, C. A., Aldape, K., Fuller, G. N., Marini, F. C., Alonso, M. M., Idoate, M. A., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.1893 · Cited by 85 · see citing works

Engagement of α4β1 integrin by fibronectin induces in vitro resistance of B chronic lymphocytic leukemia cells to fludarabine

de la Fuente, M. T., Casanova, B., Moyano, J. V., Garcı́a-Gila, M., Sanz, L., Garcia-Marco, J. A., Silva, A., & Garcı́a-Pardo, A. (2002) · Journal of Leukocyte Biology · doi:10.1189/jlb.71.3.495 · Cited by 82 · see citing works

The selective adhesion molecule inhibitor Natalizumab decreases multiple myeloma cell growth in the bone marrow microenvironment: therapeutic implications

Podar, K., Zimmerhackl, A., Fulciniti, M., Tonon, G., Hainz, U., Tai, Y., Vallet, S., Halama, N., Jäger, D., Olson, D. L., et al. (2011) · British Journal of Haematology · doi:10.1111/j.1365-2141.2011.08864.x · Cited by 76 · see citing works

A phase 1 study of a chimeric monoclonal antibody against interleukin-6, siltuximab, combined with docetaxel in patients with metastatic castration-resistant prostate cancer

Hudes, G., Tagawa, S., Whang, Y., Qi, M., Qin, X., Puchalski, T., Reddy, M., Cornfeld, M., & Eisenberger, M. (2013) · Investigational new drugs · doi:10.1007/s10637-012-9857-z · Cited by 71 · see citing works

The Disintegrin-like and Cysteine-rich domains of ADAM-9 Mediate Interactions between Melanoma Cells and Fibroblasts

Zigrino, P., Nischt, R., & Mauch, C. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.168617 · Cited by 62 · see citing works

Lymph Node Stromal Cells Enhance Drug-Resistant Colon Cancer Cell Tumor Formation through SDF-1α/CXCR4 Paracrine Signaling

Margolin, D. A., Silinsky, J., Grimes, C., Spencer, N. D., Aycock, M., Green, H., Cordova, J., Davis, N. K., Driscoll, T., & Li, L. (2011) · Neoplasia · doi:10.1593/neo.11324 · Cited by 60 · see citing works

Secretion of vascular endothelial growth factor by oral squamous cell carcinoma cells skews endothelial cells to suppress T-cell functions

Mulligan, J. K., Day, T. A., Gillespie, M. B., Rosenzweig, S. A., & Young, M. R. (2009) · Human Immunology · doi:10.1016/j.humimm.2009.01.014 · Cited by 56 · see citing works

Tumors induce the formation of suppressor endothelial cells in vivo

Mulligan, J. K., & Young, M. R. (2009) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-009-0747-y · Cited by 50 · see citing works

Inhibition of α4β1 integrin increases ovarian cancer response to carboplatin

Scalici, J. M., Harrer, C., Allen, A., Jazaeri, A. A., Atkins, K. A., McLachlan, K. R., & Slack‐Davis, J. K. (2014) · Gynecologic Oncology · doi:10.1016/j.ygyno.2013.12.031 · Cited by 36 · see citing works

The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment

Anderson, K. C. (2003) · European Journal Of Haematology · doi:10.1034/j.1600-0609.2003.t01-1-01067.x · Cited by 33 · see citing works

Bortezomib, Dexamethasone, and Fibroblast Growth Factor Receptor 3–Specific Tyrosine Kinase Inhibitor in t(4;14) Myeloma

Bisping, G., Wenning, D., Kropff, M. H., Gustavus, D., Müller‐Tidow, C., Stelljes, M., Munzert, G. M., Hilberg, F., Roth, G. J., Štefanič, M., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1612 · Cited by 33 · see citing works

Role of the extracellular matrix proteins in the resistance of SP6.5 uveal melanoma cells toward cisplatin

Bérubé, M., Talbot, M., Collin, C., Paquet‐Bouchard, C., Germain, L., Guérin, S. L., & Petitclerc, É. (2005) · International Journal of Oncology · doi:10.3892/ijo.26.2.405 · Cited by 30 · see citing works

Cilengitide treatment of newly diagnosed glioblastoma patients does not alter patterns of progression

Neyns, B. (2014) · VUBIR (Vrije Universiteit Brussel) · doi:10.1007/s11060-014-1365-x

Role of hypoxia in cancer therapy by regulating the tumor microenvironment

Jing, X., Yang, F., Shao, C., Wei, K., Xie, M., Shen, H., & Shu, Y. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1089-9 · Cited by 2,054 · see citing works

The rediscovery of platinum-based cancer therapy

Rottenberg, S., Disler, C., & Perego, P. (2020) · Nature reviews. Cancer · doi:10.1038/s41568-020-00308-y · Cited by 977 · see citing works

Radiotherapy combined with immunotherapy: the dawn of cancer treatment

Zhang, Z., Liu, X., Chen, D., & Yu, J. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01102-y · Cited by 695 · see citing works

The application of nanoparticles in cancer immunotherapy: Targeting tumor microenvironment

Yang, M., Li, J., Gu, P., & Fan, X. (2020) · Bioactive Materials · doi:10.1016/j.bioactmat.2020.12.010 · Cited by 680 · see citing works

Shaping Polarization Of Tumor-Associated Macrophages In Cancer Immunotherapy

Gao, J., Liang, Y., & Wang, L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.888713 · Cited by 565 · see citing works

Manganese Oxide Nanomaterials: Synthesis, Properties, and Theranostic Applications

Ding, B., Zheng, P., Ma, P., & Lin, J. (2020) · Advanced Materials · doi:10.1002/adma.201905823 · Cited by 523 · see citing works

Three-Dimensional Spheroids as In Vitro Preclinical Models for Cancer Research

Pinto, B., Henriques, A. C., Silva, P. M. A., & Bousbaa, H. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12121186 · Cited by 440 · see citing works

Comprehensive analysis of spatial architecture in primary liver cancer

Wu, R. T., Guo, W., Qiu, X., Wang, S., Sui, C., Lian, Q., Wu, J., Shan, Y., Zhao, Y., Yang, S., et al. (2021) · Science Advances · doi:10.1126/sciadv.abg3750 · Cited by 378 · see citing works

Nanoparticles in tumor microenvironment remodeling and cancer immunotherapy

Lü, Q., Kou, D., Lou, S., Ashrafizadeh, M., Aref, A. R., Cañadas, I., Tian, Y., Niu, X., Wang, Y. Z., Torabian, P., et al. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01535-8 · Cited by 376 · see citing works

Cancer associated-fibroblast-derived exosomes in cancer progression

Li, C., Teixeira, A. F., Zhu, H., & ten Dijke, P. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01463-y · Cited by 341 · see citing works

Capturing functional two-dimensional nanosheets from sandwich-structure vermiculite for cancer theranostics

Ji, X., Ge, L., Chuang, L. I. U., Tang, Z., Xiao, Y., Chen, W., Lei, Z., Gao, W. M., Blake, S., De, D., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21436-5 · Cited by 321 · see citing works

The Promise of Nanotechnology in Personalized Medicine

Alghamdi, M. A., Fallica, A. N., Virzì, N. F., Kesharwani, P., Pittalà, V., & Greish, K. F. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12050673 · Cited by 291 · see citing works

Wnt Signaling and Its Significance Within the Tumor Microenvironment: Novel Therapeutic Insights

Patel, S., Alam, A., Pant, R., & Chattopadhyay, S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02872 · Cited by 284 · see citing works

3D Cell Culture Models as Recapitulators of the Tumor Microenvironment for the Screening of Anti-Cancer Drugs

Barbosa, M. A. G., Xavier, C. P. R., Pereira, R. F., Petrikaitė, V., & Vasconcelos, M. H. (2021) · Cancers · doi:10.3390/cancers14010190 · Cited by 285 · see citing works

Functional precision oncology: Testing tumors with drugs to identify vulnerabilities and novel combinations

Letai, A. G., Bhola, P. D., & Welm, A. L. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.12.004 · Cited by 282 · see citing works

Current therapy and drug resistance in metastatic castration-resistant prostate cancer

Cai, M., Song, X., Li, X., Chen, M., Guo, J., Yang, D., Chen, Z., & Zhao, S. (2023) · Drug Resistance Updates · doi:10.1016/j.drup.2023.100962 · Cited by 269 · see citing works

Carbon‐Based Nanomaterials for Cancer Therapy via Targeting Tumor Microenvironment

Saleem, J., Wang, L., & Chen, C. (2018) · Advanced Healthcare Materials · doi:10.1002/adhm.201800525 · Cited by 263 · see citing works

PD-L1, TMB, MSI, and Other Predictors of Response to Immune Checkpoint Inhibitors in Biliary Tract Cancer

Rizzo, A., Ricci, A. D., & Brandi, G. (2021) · Cancers · doi:10.3390/cancers13030558 · Cited by 260 · see citing works

Single‐cell RNA sequencing in breast cancer: Understanding tumor heterogeneity and paving roads to individualized therapy

Ding, S., Chen, X., & Shen, K. (2020) · 癌症：英文版 · doi:10.1002/cac2.12078 · Cited by 267 · see citing works

Metabolic reprogramming and therapeutic resistance in primary and metastatic breast cancer

Liu, S., Zhang, X., Wang, W., Li, X., Sun, X., Zhao, Y., Wang, Q., Li, Y., Hu, F., & Ren, H. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02165-x · Cited by 279 · see citing works

A risk model developed based on tumor microenvironment predicts overall survival and associates with tumor immunity of patients with lung adenocarcinoma

Wu, J., Li, L., Zhang, H., Zhao, Y., Zhang, H., Wu, S., & Xu, B. (2021) · Oncogene · doi:10.1038/s41388-021-01853-y · Cited by 255 · see citing works

An Overview: The Diversified Role of Mitochondria in Cancer Metabolism

Liu, Y., Sun, Y., Guo, Y., Shi, X., Chen, X., Feng, W., Wu, L., Zhang, J., Yu, S., Wang, Y., et al. (2023) · International Journal of Biological Sciences · doi:10.7150/ijbs.81609 · Cited by 260 · see citing works

Advances of medical nanorobots for future cancer treatments

Kong, X., Gao, P., Wang, J., Fang, Y., & Hwang, K. C. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01463-z · Cited by 253 · see citing works

Exosomal miR-500a-5p derived from cancer-associated fibroblasts promotes breast cancer cell proliferation and metastasis through targeting USP28

Chen, B., Sang, Y., Song, X., Zhang, D., Wang, L., Zhao, W., Liang, Y., Zhang, N., & Yang, Q. (2021) · Theranostics · doi:10.7150/thno.53412 · Cited by 229 · see citing works

Enhancement of EPR Effect for Passive Tumor Targeting: Current Status and Future Perspectives

Vagena, I.-A., Malapani, C., Gatou, Μ.-A., Lаgopati, N., & Pavlatou, E. A. (2025) · Applied Sciences · doi:10.3390/app15063189 · Cited by 232 · see citing works

Cancer stem cell secretome in the tumor microenvironment: a key point for an effective personalized cancer treatment

López de Andrés, J., Griñán-Lisón, C., Jiménez, G., & Marchal, J. A. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00966-3 · Cited by 207 · see citing works

Targeted xCT‐mediated Ferroptosis and Protumoral Polarization of Macrophages Is Effective against HCC and Enhances the Efficacy of the Anti‐PD‐1/L1 Response

Tang, B., Zhu, J., Wang, Y., Chen, W., Fang, S., Mao, W., Xu, Z., Yang, Y., Weng, Q., Zhao, Z., et al. (2022) · Advanced Science · doi:10.1002/advs.202203973 · Cited by 222 · see citing works

Exploring the crosstalk between endothelial cells, immune cells, and immune checkpoints in the tumor microenvironment: new insights and therapeutic implications

Fang, J., Lu, Y., Zheng, J., Jiang, X., Shen, H., Xi, S., Lu, Y., & Fu, P. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-06119-x · Cited by 213 · see citing works

Mechanical tumor microenvironment and transduction: cytoskeleton mediates cancer cell invasion and metastasis

Li, X., & Wang, J. (2020) · International Journal of Biological Sciences · doi:10.7150/ijbs.44943 · Cited by 212 · see citing works

Viral vectored vaccines: design, development, preventive and therapeutic applications in human diseases

Wang, S., Liang, B., Wang, W., Li, L., Feng, N., Zhao, Y., Wang, T., Yan, F., Yang, S., & Xia, X. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01408-5 · Cited by 222 · see citing works

Cancer Stem Cells and Targeting Strategies

Barbato, L., Bocchetti, M., Biase, A. D., & Regad, T. (2019) · Cells · doi:10.3390/cells8080926 · Cited by 210 · see citing works

Single-cell transcriptome analysis reveals tumor immune microenvironment heterogenicity and granulocytes enrichment in colorectal cancer liver metastases

Zhang, Y., Song, J., Zhao, Z., Yang, M., Chen, M., Liu, C., Ji, J., & Zhu, D. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.10.016 · Cited by 212 · see citing works

Tumor‐derived exosomal miR‐19b‐3p facilitates M2 macrophage polarization and exosomal LINC00273 secretion to promote lung adenocarcinoma metastasis via Hippo pathway

Chen, J., Zhang, K., Zhi, Y., Wu, Y., Chen, B., Bai, J., & Wang, X. (2021) · Clinical and Translational Medicine · doi:10.1002/ctm2.478 · Cited by 206 · see citing works

Exosomes and breast cancer drug resistance

Dong, X., Bai, X., Ni, J., Zhang, H., Duan, W., Graham, P., & Li, Y. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-03189-z · Cited by 202 · see citing works

Metabolism in tumor microenvironment: Implications for cancer immunotherapy

Shi, R., Tang, Y., & Miao, H. (2020) · MedComm · doi:10.1002/mco2.6 · Cited by 198 · see citing works

Chlorin e6: A Promising Photosensitizer in Photo-Based Cancer Nanomedicine

Hak, A., Ali, M. S., Sankaranarayanan, S. A., Shinde, V. R., & Rengan, A. K. (2023) · ACS Applied Bio Materials · doi:10.1021/acsabm.2c00891 · Cited by 186 · see citing works

Single-cell RNA sequencing reveals the tumor microenvironment and facilitates strategic choices to circumvent treatment failure in a chemorefractory bladder cancer patient

Lee, H. W., Chung, W., Lee, H., Jeong, D. E., Jo, A., Lim, J. E., Hong, J. H., Nam, D., Jeong, B. C., Park, S. H., et al. (2020) · Genome Medicine · doi:10.1186/s13073-020-00741-6 · Cited by 184 · see citing works

Nanoparticle Drug Delivery System for Glioma and Its Efficacy Improvement Strategies: A Comprehensive Review

Li, J., Zhao, J., Tan, T., Liu, M., Zeng, Z., Zeng, Y., Zhang, L., Fu, C., Chen, D., & Xie, T. (2020) · International Journal of Nanomedicine · doi:10.2147/ijn.s243223 · Cited by 182 · see citing works

METTL3 restrains papillary thyroid cancer progression via m6A/c-Rel/IL-8-mediated neutrophil infiltration

He, J., Zhou, M., Yin, J., Wan, J., Chu, J., Jia, J., Sheng, J., Wang, C., Yin, H., & He, F. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.01.019 · Cited by 182 · see citing works

Single-Cell Transcriptome Analysis Reveals Intratumoral Heterogeneity in ccRCC, which Results in Different Clinical Outcomes

Hu, J., Chen, Z., Bao, L., Zhou, L., Hou, Y., Liu, L., Xiong, M., Zhang, Y., Wang, B., Tao, Z., et al. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.04.023 · Cited by 180 · see citing works

3D Tumor Models and Their Use for the Testing of Immunotherapies

Boucherit, N., Gorvel, L., & Olive, D. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.603640 · Cited by 177 · see citing works

TLR 7/8 agonist reverses oxaliplatin resistance in colorectal cancer via directing the myeloid-derived suppressor cells to tumoricidal M1-macrophages

Liu, Z., Xie, Y., Xiong, Y., Liu, S., Qiu, C., Zhu, Z., Mao, H., Yu, M., & Wang, X. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.10.020 · Cited by 165 · see citing works

Patient-derived organoids in precision cancer medicine

Tong, L., Cui, W., Zhang, B., Fonseca, P., Zhao, Q. C., Zhang, P., Xu, B., Zhang, Q., Li, Z., Seashore-Ludlow, B. A., et al. (2024) · Med · doi:10.1016/j.medj.2024.08.010 · Cited by 173 · see citing works

Design of a two-dimensional interplanar heterojunction for catalytic cancer therapy

Kang, Y., Mao, Z., Wang, Y., Pan, C., Ou, M., Zhang, H., Zeng, W., & Ji, X. (2022) · Nature Communications · doi:10.1038/s41467-022-30166-1 · Cited by 160 · see citing works

Tumor microenvironment: an evil nexus promoting aggressive head and neck squamous cell carcinoma and avenue for targeted therapy

Bhat, A. A., Yousuf, P., Wani, N. A., Rizwan, A., Chauhan, S. S., Siddiqi, M. A., Bedognetti, D., El-Rifai, W. M., Frenneaux, M. P., Batra, S. K., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00419-w · Cited by 157 · see citing works

Reactive Oxygen Species and Antitumor Immunity—From Surveillance to Evasion

Kotsafti, A., Scarpa, M., Castagliuolo, I., & Scarpa, M. (2020) · Cancers · doi:10.3390/cancers12071748 · Cited by 157 · see citing works

Cancer-derived exosomal TRIM59 regulates macrophage NLRP3 inflammasome activation to promote lung cancer progression

Liang, M., Chen, X., Wang, L., Qin, L., Wang, H., Sun, Z., Zhao, W., & Geng, B. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01688-7 · Cited by 154 · see citing works

Targeting Oxidatively Induced DNA Damage Response in Cancer: Opportunities for Novel Cancer Therapies

Davalli, P., Marverti, G., Lauriola, A., & D’Arca, D. (2018) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2018/2389523 · Cited by 151 · see citing works

CD63 + Cancer‐Associated Fibroblasts Confer Tamoxifen Resistance to Breast Cancer Cells through Exosomal miR‐22

Gao, Y., Li, X., Zeng, C., Liu, C., Hao, Q., Li, W., Zhang, K., Zhang, W., Wang, S., Zhao, H., et al. (2020) · Advanced Science · doi:10.1002/advs.202002518 · Cited by 149 · see citing works

Heparanase-driven sequential released nanoparticles for ferroptosis and tumor microenvironment modulations synergism in breast cancer therapy

Zhang, J., Yang, J., Zuo, T., Ma, S., Xokrat, N., Hu, Z., Wang, Z., Xu, R., Wei, Y., & Shen, Q. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120429 · Cited by 143 · see citing works

Exploring the dynamic interplay between cancer stem cells and the tumor microenvironment: implications for novel therapeutic strategies

Li, Y.-R., Fang, Y., Lyu, Z., Zhu, Y., & Yang, L. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04575-9 · Cited by 149 · see citing works

The Tumor Microenvironment in Tumorigenesis and Therapy Resistance Revisited

Dzobo, K., Senthebane, D. A., & Dandara, C. (2023) · Cancers · doi:10.3390/cancers15020376 · Cited by 146 · see citing works

Extracellular vesicles as a novel source of biomarkers in liquid biopsies for monitoring cancer progression and drug resistance

Vasconcelos, M. H., Caires, H. R., Ābols, A., Xavier, C. P. R., & Linē, A. (2019) · Drug Resistance Updates · doi:10.1016/j.drup.2019.100647 · Cited by 144 · see citing works

Tumor Microenvironment: Implications in Melanoma Resistance to Targeted Therapy and Immunotherapy

Falcone, I., Conciatori, F., Bazzichetto, C., Ferretti, G., Cognetti, F., Ciuffreda, L., & Milella, M. (2020) · Cancers · doi:10.3390/cancers12102870 · Cited by 147 · see citing works

Metabolism of Dendritic Cells in Tumor Microenvironment: For Immunotherapy

Peng, X., He, Y., Huang, J. X., Tao, Y., & Liu, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.613492 · Cited by 146 · see citing works

Promotion of epithelial-mesenchymal transformation by hepatocellular carcinoma-educated macrophages through Wnt2b/β-catenin/c-Myc signaling and reprogramming glycolysis

Yu, J., Han, Q., Zhao, H., & Zhang, J. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01808-3 · Cited by 143 · see citing works

Cell Culture Based in vitro Test Systems for Anticancer Drug Screening

Kitaeva, K. V., Rutland, C. S., Rizvanov, A. A., & Solovyeva, V. V. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.00322 · Cited by 142 · see citing works

M2 macrophage-derived exosomes promote lung adenocarcinoma progression by delivering miR-942

Wei, K., Ma, Z., Yang, F., Zhao, X., Jiang, W., Pan, C., Li, Z., Pan, X., He, Z., Xu, J., et al. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.10.045 · Cited by 141 · see citing works

Targeting the tumor microenvironment in B-cell lymphoma: challenges and opportunities

Liu, Y., Zhou, X., & Wang, X. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01134-x · Cited by 139 · see citing works

The Impact of TRPV1 on Cancer Pathogenesis and Therapy: A Systematic Review

Li, L., Chen, C., Chiang, C., Xiao, T., Chen, Y., Zhao, Y., & Zheng, D. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.59918 · Cited by 132 · see citing works

Spatial transcriptomics atlas reveals the crosstalk between cancer-associated fibroblasts and tumor microenvironment components in colorectal cancer

Peng, Z., Ye, M., Ding, H., Feng, Z., & Hu, K. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03510-8 · Cited by 135 · see citing works

Cancer Spheroids and Organoids as Novel Tools for Research and Therapy: State of the Art and Challenges to Guide Precision Medicine

Harane, S. E., Zidi, B., Harane, N. E., Krause, K., Matthes, T., & Preynat‐Seauve, O. (2023) · Cells · doi:10.3390/cells12071001 · Cited by 132 · see citing works

Unleashing the potential of combining FGFR inhibitor and immune checkpoint blockade for FGF/FGFR signaling in tumor microenvironment

Ruan, R., Li, L., Li, X., Huang, C., Zhanmin, Z., Zhong, H., Zeng, S., Shi, Q., Yang, X., Zeng, Q., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01761-7 · Cited by 130 · see citing works

Low tumor purity is associated with poor prognosis, heavy mutation burden, and intense immune phenotype in colon cancer

Mao, Y., Feng, Q., Zheng, P., Yang, L., Liu, T., Xu, Y., Zhu, D., Chang, W., Ji, M., Ren, L., et al. (2018) · Cancer Management and Research · doi:10.2147/cmar.s171855 · Cited by 128 · see citing works

Cisplatin-activated PAI-1 secretion in the cancer-associated fibroblasts with paracrine effects promoting esophageal squamous cell carcinoma progression and causing chemoresistance

Che, Y., Wang, J., Li, Y., Lu, Z., Huang, J., Sun, S., Mao, S., Lei, Y., Zang, R., Sun, N., et al. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0808-2 · Cited by 126 · see citing works

Machine learning and data mining frameworks for predicting drug response in cancer: An overview and a novel in silico screening process based on association rule mining

Vougas, K. N., Sakellaropoulos, T., Kotsinas, A., Foukas, G.-R. P., Ntargaras, A., Koinis, F., Polyzos, A., Myrianthopoulos, V., Zhou, H., Narang, S., et al. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107395 · Cited by 124 · see citing works

Radiotherapy induced immunogenic cell death by remodeling tumor immune microenvironment

Zhu, S., Wang, Y., Tang, J., & Cao, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1074477 · Cited by 127 · see citing works

LncRNA-encoded peptides in cancer

Zhang, Y. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01591-0 · Cited by 129 · see citing works

Role of the mechanical microenvironment in cancer development and progression

Liu, Q., Luo, Q., Ju, Y., & Song, G. (2020) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2019.0437 · Cited by 121 · see citing works

Targeting tumor-associated macrophages for cancer immunotherapy

Shu, Y., & Cheng, P. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188434 · Cited by 122 · see citing works

Cancer-associated fibroblasts: Vital suppressors of the immune response in the tumor microenvironment

Xiang, X., Niu, Y., Wang, Z.-H., Ye, L., Peng, W., & Zhou, Q. (2022) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2022.07.006 · Cited by 120 · see citing works

Immune-checkpoint inhibitor resistance in cancer treatment: Current progress and future directions

Zhang, C., Zhang, C., & Wang, H. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216182 · Cited by 125 · see citing works

Microbiota and prostate cancer

Rizzo, A., Santoni, M., Mollica, V., Fiorentino, M., Brandi, G., & Massari, F. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.09.007 · Cited by 119 · see citing works

Therapeutic resistance of pancreatic cancer: Roadmap to its reversal

Yu, S., Zhang, C., & Xie, K. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188461 · Cited by 117 · see citing works

Liver metastasis from colorectal cancer: pathogenetic development, immune landscape of the tumour microenvironment and therapeutic approaches

Wang, Y., Zhong, X., He, X., Hu, Z., Huang, H., Chen, J., Chen, K., Zhao, S., Wei, P., & Li, D. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02729-7 · Cited by 119 · see citing works

Comprehensive analysis of the association between tumor glycolysis and immune/inflammation function in breast cancer

Li, W., Xu, M. L., Li, Y., Huang, Z., Zhou, J., Zhao, Q., Le, K., Dong, F., Wan, C., & Yi, P. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-020-02267-2 · Cited by 115 · see citing works

Hyperthermia Targeting the Tumor Microenvironment Facilitates Immune Checkpoint Inhibitors

Li, Z., Deng, J., Sun, J., & Ma, Y. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.595207 · Cited by 118 · see citing works

Combination therapy based on nano codelivery for overcoming cancer drug resistance

Wang, H., & Huang, Y. (2020) · Medicine in Drug Discovery · doi:10.1016/j.medidd.2020.100024 · Cited by 115 · see citing works

Ferroptosis‐related gene signature associates with immunity and predicts prognosis accurately in patients with osteosarcoma

Lei, T., Hu, Q., Lei, P., & Hu, Y. (2021) · Cancer Science · doi:10.1111/cas.15131 · Cited by 114 · see citing works

M2 macrophage-derived extracellular vesicles facilitate CD8+T cell exhaustion in hepatocellular carcinoma via the miR-21-5p/YOD1/YAP/β-catenin pathway

Pu, J., Xu, Z., Nian, J., Fang, Q., Yang, M., Huang, Y., Li, W., Ge, B., Wang, J., & Wei, H. (2021) · Cell Death Discovery · doi:10.1038/s41420-021-00556-3 · Cited by 114 · see citing works

Role of Exosomal miRNAs and the Tumor Microenvironment in Drug Resistance

dos Santos, P. W. D. S., & Almeida, F. B. D. R. (2020) · Cells · doi:10.3390/cells9061450 · Cited by 112 · see citing works

Prognostic Significance and Tumor Immune Microenvironment Heterogenicity of m5C RNA Methylation Regulators in Triple-Negative Breast Cancer

Huang, Z., Pan, J., Wang, H., Du, X., Xu, Y., Wang, Z., & Chen, D. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.657547 · Cited by 113 · see citing works

TNFSF14: LIGHTing the Way for Effective Cancer Immunotherapy

Skeate, J. G., Otsmaa, M., Prins, R., Fernandez, D. J., Silva, D. M. D., & Kast, W. M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00922 · Cited by 111 · see citing works

Systematic Pan-Cancer Analysis Identifies TREM2 as an Immunological and Prognostic Biomarker

Cheng, X. M., Wang, X., Nie, K., Cheng, L., Zhang, Z., Hu, Y., & Peng, W. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.646523 · Cited by 111 · see citing works

Targeted inhibition of tumor-derived exosomes as a novel therapeutic option for cancer

Li, Y., Chen, Z.-K., Duan, X., Zhang, H., Xiao, B.-L., Wang, K.-M., & Chen, G. (2022) · Experimental & Molecular Medicine · doi:10.1038/s12276-022-00856-3 · Cited by 112 · see citing works

Tumour Heterogeneity of Breast Cancer: From Morphology to Personalised Medicine

Aleskandarany, M. A., Vandenberghe, M. E., Marchiò, C., Ellis, I. O., Sapino, A., & Rakha, E. A. (2018) · Pathobiology · doi:10.1159/000477851 · Cited by 109 · see citing works

Prognostic value of inflammatory markers NLR, PLR, and LMR in gastric cancer patients treated with immune checkpoint inhibitors: a meta-analysis and systematic review

Tan, S., Zheng, Q., Zhang, W., Zhou, M., Xia, C., & Feng, W. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1408700 · Cited by 108 · see citing works

Translating complexity and heterogeneity of pancreatic tumor: 3D in vitro to in vivo models

Heinrich, M. A., Mostafa, A. M. R. H., Morton, J. P., Hawinkels, L. J. A. C., & Prakash, J. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.04.018 · Cited by 109 · see citing works

Tumor microenvironment-responsive dynamic inorganic nanoassemblies for cancer imaging and treatment

Yang, Y. P., Wu, H., Liu, B., & Liu, Z. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.114004 · Cited by 107 · see citing works

Tumour Microenvironment (TME) Characterization Identified Prognosis and Immunotherapy Response in Muscle-Invasive Bladder Cancer (MIBC)

Cao, R., Yuan, L., Ma, B., Wang, G., Qiu, W., & Tian, Y. (2019) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02649-x · Cited by 107 · see citing works

Immunotherapy discovery on tumor organoid-on-a-chip platforms that recapitulate the tumor microenvironment

Zhang, J., Tavakoli, H., Ma, L., Li, X., Han, L., & Li, X. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114365 · Cited by 110 · see citing works

Hypoxia promotes non-small cell lung cancer cell stemness, migration, and invasion via promoting glycolysis by lactylation of SOX9

Yan, F., Teng, Y., Li, X., Zhong, Y., Li, C., Yan, F., & He, X. (2024) · Cancer Biology & Therapy · doi:10.1080/15384047.2024.2304161 · Cited by 106 · see citing works

Bimetallic Oxide FeWOX Nanosheets as Multifunctional Cascade Bioreactors for Tumor Microenvironment‐Modulation and Enhanced Multimodal Cancer Therapy

Gong, F., Chen, M., Yang, N., Dong, Z., Tian, L., Hao, Y., Zhuo, M., Liu, Z., Chen, Q., & Cheng, L. (2020) · Advanced Functional Materials · doi:10.1002/adfm.202002753 · Cited by 104 · see citing works

Engineered nanoparticles for precise targeted drug delivery and enhanced therapeutic efficacy in cancer immunotherapy

Peng, X., Fang, J., Lou, C., Yang, L., Shan, S., Wang, Z., Chen, Y., Li, H., & Li, X. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.05.010 · Cited by 109 · see citing works

Carcinoma-Associated Mesenchymal Stem/Stromal Cells: Architects of the Pro-tumorigenic Tumor Microenvironment

Frisbie, L. G., Buckanovich, R. J., & Coffman, L. G. (2022) · Stem Cells · doi:10.1093/stmcls/sxac036 · Cited by 107 · see citing works

Porphyrin‐Based Covalent Organic Framework for Imaging‐Guided Cancer Combinatorial Immuno‐Sonodynamic Therapy

Lu, Z.-X., Bai, S., Jiang, Y., Wu, S., Xu, D., Chen, Y., Lan, Y., An, Y.-B., Mao, J.-S., Liu, X., et al. (2022) · Advanced Functional Materials · doi:10.1002/adfm.202207749 · Cited by 80 · see citing works

MYC and therapy resistance in cancer: risks and opportunities

Donati, G., & Amati, B. B. (2022) · Molecular Oncology · doi:10.1002/1878-0261.13319 · Cited by 99 · see citing works

Modifying the tumour microenvironment and reverting tumour cells: New strategies for treating malignant tumours

Cheng, Y., Wang, S. B., Liu, J. H., Jin, L., Liu, Y., Li, C. Y., Su, Y., Liu, Y. R., Sang, X., Wan, Q., et al. (2020) · Cell Proliferation · doi:10.1111/cpr.12865 · Cited by 96 · see citing works

Artificial Intelligence to Decode Cancer Mechanism: Beyond Patient Stratification for Precision Oncology

Patel, S. K., George, B., & Rai, V. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.01177 · Cited by 100 · see citing works

Targeting MDSC for Immune-Checkpoint Blockade in Cancer Immunotherapy: Current Progress and New Prospects

Li, T., Liu, T., Zhu, W., Xie, S., Zhao, Z., Feng, B., Guo, H., & Yang, R. (2021) · Clinical Medicine Insights Oncology · doi:10.1177/11795549211035540 · Cited by 94 · see citing works

Microenvironmental regulation of therapeutic response in cancer

Klemm, F., & Joyce, J. A. (2014) · Trends in Cell Biology · doi:10.1016/j.tcb.2014.11.006 · Cited by 769 · see citing works

Tumor microenvironment as a therapeutic target in cancer

Xiao, Y. Q., & Yu, D. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107753 · Cited by 1,977 · see citing works

From immune exclusion to exhaustion: tumor microenvironment drives therapy response

Maletin, N. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1785587 · Cited by 13 · see citing works

Tumor Microenvironment and Drug Response: A Pathology–pharmacology Perspective on Mechanisms of Therapeutic Resistance

Ravichandran, S., & Vilvanathan, S. (2026) · doi:10.9734/ajmpcp/2026/v9i1402

Potential Strategies to Improve the Effectiveness of Drug Therapy by Changing Factors Related to Tumor Microenvironment

Cao, D., Naiyila, X., Li, J., Huang, Y. C., Chen, Z., Chen, B., Li, J., Guo, J., Dong, Q., Ai, J., et al. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.705280 · Cited by 7 · see citing works